The EMA, the FDA, and Health Canada head to head
A recent issue of the New England Journal of Medicine carried an article comparing the regulatory review times of novel therapeutics by three different regulatory agencies (FDA, EMA, and Health Canada).
In a previous column, I talked about the importance of review cycles, and also about how inefficient they can be. In particular, the column talked about how some reviewers inappropriately focus on certain details while failing to address high-level failings. Another essential aspect of a successful review cycle is of course the resolution of comments.
Download Full Article
You must be a member of EMWA in order to download the full article.
EMWA members please log in to download the full article.
If you would like to become a member of EMWA, please join here.